文献速递湿疹皮炎与荨麻疹

选择性鞘氨醇1-磷酸受体调节剂依曲莫德治疗中重度特应性皮炎成人患者的疗效与安全性(ADVISE研究)

Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-02-13

ADVISE是一项2期随机双盲安慰剂对照试验,140例中重度特应性皮炎成人按1:1:1随机接受依曲莫德2 mg、1 mg或安慰剂每日一次治疗12周。主要终点EASI评分较基线变化百分比在2 mg组为-57.2%、安慰剂组为-48.4%(p=0.18),未达统计学显著;2 mg组vIGA-AD 0/1且改善≥2分的比例显著高于安慰剂(29.8% vs 13.0%,p=0.045),EASI-75无统计学显著差异。两种剂量耐受性良好,无严重不良事件或死亡。

要点

  • 主要终点未达到:第12周EASI评分较基线变化百分比2 mg组-57.2% vs 安慰剂组-48.4%(p=0.18)。
  • 2 mg组vIGA-AD 0/1且改善≥2分比例显著高于安慰剂(29.8% vs 13.0%,p=0.045)。
  • EASI-75应答与安慰剂相比无统计学显著差异;两种剂量耐受性良好,无严重不良事件或死亡。

核心结论

  • 主要终点未达到,但依曲莫德2 mg在多项临床医生和患者评估指标上观察到疗效。
  • 1 mg和2 mg剂量均耐受性良好,作者认为需进一步临床研究以评估依曲莫德在特应性皮炎中的价值。

研究设计与样本

  • 2期随机双盲安慰剂对照试验,纳入≥18岁中重度特应性皮炎成人患者。
  • 入组标准为基线vIGA-AD评分≥3、EASI评分≥16、体表面积受累≥10%。
  • 140例参与者按1:1:1随机接受每日一次口服依曲莫德2 mg(n=47)、1 mg(n=47)或安慰剂(n=46),治疗12周。
  • 主要终点为第12周EASI评分较基线变化百分比,在全分析集(所有随机参与者)中评估。

主要发现

  • 第12周EASI评分较基线变化百分比:依曲莫德2 mg组-57.2% vs 安慰剂组-48.4%(p=0.18)。
  • 第12周达到vIGA-AD评分0或1且较基线改善≥2分的比例:依曲莫德2 mg组29.8% vs 安慰剂组13.0%(p=0.045)。
  • EASI-75应答与安慰剂相比无统计学显著差异。
  • 治疗中出现的不良事件发生率:依曲莫德2 mg组59.6%、1 mg组40.4%、安慰剂组47.8%。
  • 未发生严重不良事件或死亡。

局限性

  • 原文结论指出主要终点未达到。
  • EASI-75应答与安慰剂相比无统计学显著差异。
  • 作者在结论中提出需进一步临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Etrasimod is an oral, selective, sphingosine 1-phosphate (S1P) receptor1,4,5 modulator in development for immune-mediated inflammatory disorders. Efficacy and safety of orally administered S1P receptor modulation in atopic dermatitis (AD) have not yet been examined. OBJECTIVE: To assess the efficacy and safety of etrasimod monotherapy in adults with moderate-to-severe AD. METHODS: In this phase 2, randomized, double-blind, placebo-controlled trial, participants (≥18 years) with moderate-to-severe AD defined as baseline validated Investigator's Global Assessment (vIGA-AD) score ≥ 3, Eczema Area and Severity Index (EASI) score ≥ 16, and body surface area involvement ≥10% were randomized 1:1:1 to once-daily oral etrasimod 1 mg, 2 mg or placebo for 12 weeks. The primary outcome was percent change in EASI score from baseline at week 12, assessed in the Full Analysis Set (all randomized participants). Key secondary outcomes were achievement of a vIGA-AD score of 0 or 1 with a ≥2-point improvement from baseline and EASI-75 response at Week 12. Safety was assessed during the double-blind period. RESULTS: One hundred and forty participants were randomized to etrasimod 2 mg (n = 47), 1 mg (n = 47) or placebo (n = 46). At Week 12, percent change in EASI score was -57.2% in the etrasimod 2-mg group versus -48.4% in the placebo group (p = 0.18). A significantly greater proportion of participants receiving etrasimod 2 mg achieved vIGA-AD scores of 0 or 1 with a ≥2-point improvement at Week 12 versus placebo (29.8% vs. 13.0%; p = 0.045); however, EASI-75 response was not statistically significant versus placebo. Treatment-emergent adverse events (AEs) occurred in 59.6%, 40.4% and 47.8% of participants receiving etrasimod 2 mg, 1 mg and placebo, respectively. There were no serious AEs or deaths. CONCLUSIONS: The primary outcome was not met, although efficacy was observed for etrasimod 2 mg on several clinician- and patient-assessed measures, and both 1- and 2-mg doses were well tolerated, warranting further clinical investigation in AD.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Bissonnette R, Kircik L, et al. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE). J Eur Acad Dermatol Venereol. 2023. PMID: 36695074. doi:10.1111/jdv.18914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。